Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Veracyte (VCYT) EBT (2016 - 2025)

Historic EBT for Veracyte (VCYT) over the last 14 years, with Q3 2025 value amounting to $18.9 million.

  • Veracyte's EBT rose 1211.42% to $18.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $31.0 million, marking a year-over-year increase of 47951.29%. This contributed to the annual value of $25.7 million for FY2024, which is 13360.31% up from last year.
  • Veracyte's EBT amounted to $18.9 million in Q3 2025, which was up 1211.42% from $1.2 million recorded in Q2 2025.
  • Veracyte's 5-year EBT high stood at $18.9 million for Q3 2025, and its period low was -$45.7 million during Q1 2021.
  • Its 5-year average for EBT is -$7.4 million, with a median of -$8.3 million in 2023.
  • In the last 5 years, Veracyte's EBT tumbled by 78555.65% in 2023 and then skyrocketed by 48930.82% in 2025.
  • Veracyte's EBT (Quarter) stood at -$11.3 million in 2021, then skyrocketed by 69.59% to -$3.4 million in 2022, then tumbled by 785.56% to -$30.5 million in 2023, then skyrocketed by 111.3% to $3.4 million in 2024, then soared by 448.62% to $18.9 million in 2025.
  • Its last three reported values are $18.9 million in Q3 2025, $1.2 million for Q2 2025, and $7.4 million during Q1 2025.